- Home
- EARN vs ACHV Comparison
EARN vs ACHV Comparison
Compare EARN & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EARN
- ACHV
- Stock Information
- Founded
- EARN 2012
- ACHV N/A
- Country
- EARN United States
- ACHV United States
- Employees
- EARN N/A
- ACHV N/A
- Industry
- EARN Real Estate Investment Trusts
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EARN Real Estate
- ACHV Health Care
- Exchange
- EARN Nasdaq
- ACHV Nasdaq
- Market Cap
- EARN 223.5M
- ACHV 131.3M
- IPO Year
- EARN 2013
- ACHV N/A
- Fundamental
- Price
- EARN $5.71
- ACHV $2.99
- Analyst Decision
- EARN Buy
- ACHV Strong Buy
- Analyst Count
- EARN 2
- ACHV 2
- Target Price
- EARN $6.13
- ACHV $16.00
- AVG Volume (30 Days)
- EARN 296.9K
- ACHV 1.6M
- Earning Date
- EARN 11-11-2025
- ACHV 11-06-2025
- Dividend Yield
- EARN 16.87%
- ACHV N/A
- EPS Growth
- EARN N/A
- ACHV N/A
- EPS
- EARN N/A
- ACHV N/A
- Revenue
- EARN $35,893,000.00
- ACHV N/A
- Revenue This Year
- EARN N/A
- ACHV N/A
- Revenue Next Year
- EARN $15.96
- ACHV N/A
- P/E Ratio
- EARN N/A
- ACHV N/A
- Revenue Growth
- EARN 43.30
- ACHV N/A
- 52 Week Low
- EARN $4.33
- ACHV $1.84
- 52 Week High
- EARN $7.11
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- EARN 50.19
- ACHV 52.28
- Support Level
- EARN $5.62
- ACHV $2.97
- Resistance Level
- EARN $5.70
- ACHV $3.30
- Average True Range (ATR)
- EARN 0.08
- ACHV 0.21
- MACD
- EARN 0.00
- ACHV -0.00
- Stochastic Oscillator
- EARN 45.45
- ACHV 49.97
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics, and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.